Found 152 hits Enz. Inhib. hit(s) with all data for entry = 8029 Target/Host
(Institution) | Ligand | Target/Host
Links | Ligand
Links | Trg + Lig
Links | Ki
nM | ΔG°
kJ/mole | IC50
nM | Kd
nM | EC50/IC50
nM | koff
s-1 | kon
M-1s-1 | pH | Temp
°C |
|---|
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230130
(US10106559, Example 61 | US10435415, Example 61 | ...)Show SMILES Cn1c2c(F)cccc2c(=O)n(-c2cccc(c2Cl)-c2c(F)cc(C(N)=O)c3[nH]c4cc(ccc4c23)C(C)(C)O)c1=O |(4.22,-6.93,;4.22,-5.39,;5.55,-4.62,;6.89,-5.39,;6.89,-6.93,;8.22,-4.62,;8.22,-3.08,;6.89,-2.31,;5.55,-3.08,;4.22,-2.31,;4.22,-.77,;2.89,-3.08,;1.55,-2.31,;.22,-3.08,;-1.12,-2.31,;-1.12,-.77,;.22,,;1.55,-.77,;2.89,,;.22,1.54,;1.55,2.31,;2.89,1.54,;1.55,3.85,;.22,4.62,;.22,6.16,;1.55,6.93,;-1.12,6.93,;-1.12,3.85,;-2.58,4.33,;-3.49,3.08,;-5.02,2.92,;-5.64,1.51,;-4.74,.27,;-3.21,.43,;-2.58,1.83,;-1.12,2.31,;-7.13,1.11,;-6.73,-.37,;-8.22,.02,;-8.22,2.2,;2.89,-4.62,;1.55,-5.39,)| Show InChI InChI=1S/C31H23ClF2N4O4/c1-31(2,42)14-10-11-15-21(12-14)36-26-18(28(35)39)13-20(34)23(24(15)26)16-6-5-9-22(25(16)32)38-29(40)17-7-4-8-19(33)27(17)37(3)30(38)41/h4-13,36,42H,1-3H3,(H2,35,39) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.180 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230150
(US9334290, 31)Show SMILES Cc1c(cccc1-n1c(=O)cc2c(Cl)cccn2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(1.33,8.47,;1.33,6.93,;,6.16,;,4.62,;1.33,3.85,;2.67,4.62,;2.67,6.16,;4,6.93,;4,8.47,;2.67,9.24,;5.33,9.24,;6.67,8.47,;8,9.24,;8,10.78,;9.34,8.47,;9.34,6.93,;8,6.16,;6.67,6.93,;5.33,6.16,;5.33,4.62,;-1.33,6.93,;-1.33,8.47,;,9.24,;-2.67,9.24,;-4,8.47,;-5.33,9.24,;-6.67,8.47,;-5.33,10.78,;-4,6.93,;-5.15,5.9,;-4.52,4.49,;-5.15,3.09,;-4.24,1.84,;-2.71,2,;-2.08,3.41,;-2.99,4.65,;-2.67,6.16,;-4.87,.43,;-5.49,-.97,;-3.46,-.19,;-6.27,1.06,)| Show InChI InChI=1S/C31H24ClFN4O4/c1-15-17(6-4-8-23(15)37-25(38)14-24-20(32)7-5-11-36(24)30(37)40)26-21(33)13-19(29(34)39)28-27(26)18-10-9-16(31(2,3)41)12-22(18)35-28/h4-14,35,41H,1-3H3,(H2,34,39) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.190 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230154
(US9334290, 41)Show SMILES Cc1c(cccc1-n1c(=O)cc2c(F)cccn2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(1.33,8.47,;1.33,6.93,;,6.16,;,4.62,;1.33,3.85,;2.67,4.62,;2.67,6.16,;4,6.93,;4,8.47,;2.67,9.24,;5.33,9.24,;6.67,8.47,;8,9.24,;8,10.78,;9.34,8.47,;9.34,6.93,;8,6.16,;6.67,6.93,;5.33,6.16,;5.33,4.62,;-1.33,6.93,;-1.33,8.47,;,9.24,;-2.67,9.24,;-4,8.47,;-5.33,9.24,;-6.67,8.47,;-5.33,10.78,;-4,6.93,;-5.15,5.9,;-4.52,4.49,;-5.15,3.09,;-4.24,1.84,;-2.71,2,;-2.08,3.41,;-2.99,4.65,;-2.67,6.16,;-4.87,.43,;-5.49,-.97,;-3.46,-.19,;-6.27,1.06,)| Show InChI InChI=1S/C31H24F2N4O4/c1-15-17(6-4-8-23(15)37-25(38)14-24-20(32)7-5-11-36(24)30(37)40)26-21(33)13-19(29(34)39)28-27(26)18-10-9-16(31(2,3)41)12-22(18)35-28/h4-14,35,41H,1-3H3,(H2,34,39) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230106
(US10106559, Example 31 | US10435415, Example 31 | ...)Show SMILES Cc1c(cccc1-n1c(=O)cc2c(Cl)cccn2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(3.03,,;1.7,-.77,;.37,,;-.97,-.77,;-.97,-2.31,;.37,-3.08,;1.7,-2.31,;3.03,-3.08,;3.03,-4.62,;1.7,-5.39,;4.37,-5.39,;5.7,-4.62,;7.03,-5.39,;7.03,-6.93,;8.37,-4.62,;8.37,-3.08,;7.03,-2.31,;5.7,-3.08,;4.37,-2.31,;4.37,-.77,;.37,1.54,;1.7,2.31,;3.03,1.54,;1.7,3.85,;.37,4.62,;.37,6.16,;1.7,6.93,;-.97,6.93,;-.97,3.85,;-2.43,4.33,;-3.34,3.08,;-4.87,2.92,;-5.49,1.51,;-4.59,.27,;-3.06,.43,;-2.43,1.83,;-.97,2.31,;-7.03,1.51,;-7.03,-.03,;-8.37,.74,;-7.8,2.85,)| Show InChI InChI=1S/C31H24ClFN4O4/c1-15-17(6-4-8-23(15)37-25(38)14-24-20(32)7-5-11-36(24)30(37)40)26-21(33)13-19(29(34)39)28-27(26)18-10-9-16(31(2,3)41)12-22(18)35-28/h4-14,35,41H,1-3H3,(H2,34,39) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.220 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230128
(US10106559, Example 57 | US10435415, Example 57 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3C[C@H](CCc3c12)C(C)(C)O |r,wD:33.43,(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.25 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230108
(US10106559, Example 36 | US10435415, Example 36 | ...)Show SMILES Cc1c(cccc1-n1c(=O)cc2c(F)cccn2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(3.03,,;1.7,-.77,;.37,,;-.97,-.77,;-.97,-2.31,;.37,-3.08,;1.7,-2.31,;3.03,-3.08,;3.03,-4.62,;1.7,-5.39,;4.37,-5.39,;5.7,-4.62,;7.03,-5.39,;7.03,-6.93,;8.37,-4.62,;8.37,-3.08,;7.03,-2.31,;5.7,-3.08,;4.37,-2.31,;4.37,-.77,;.37,1.54,;1.7,2.31,;3.03,1.54,;1.7,3.85,;.37,4.62,;.37,6.16,;1.7,6.93,;-.97,6.93,;-.97,3.85,;-2.43,4.33,;-3.34,3.08,;-4.87,2.92,;-5.49,1.51,;-4.59,.27,;-3.06,.43,;-2.43,1.83,;-.97,2.31,;-7.03,1.51,;-6.64,.02,;-8.37,.74,;-7.8,2.85,)| Show InChI InChI=1S/C31H24ClFN4O4/c1-15-17(6-4-8-23(15)37-25(38)14-24-21(33)7-5-11-36(24)30(37)40)26-20(32)13-19(29(34)39)28-27(26)18-10-9-16(31(2,3)41)12-22(18)35-28/h4-14,35,41H,1-3H3,(H2,34,39) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.25 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.260 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230126
(US10106559, Example 56 | US10435415, Example 59 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cccc2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3C[C@H](CCc3c12)C(C)(C)O |r,wD:32.42,(2.89,,;1.55,-.77,;.22,,;-1.12,-.77,;-1.12,-2.31,;.22,-3.08,;1.55,-2.31,;2.89,-3.08,;2.89,-4.62,;1.55,-5.39,;4.22,-5.39,;5.55,-4.62,;6.89,-5.39,;6.89,-6.93,;8.22,-4.62,;8.22,-3.08,;6.89,-2.31,;5.55,-3.08,;4.22,-2.31,;4.22,-.77,;.22,1.54,;1.55,2.31,;2.89,1.54,;1.55,3.85,;.22,4.62,;.22,6.16,;1.55,6.93,;-1.12,6.93,;-1.12,3.85,;-2.58,4.33,;-3.49,3.08,;-5.02,2.92,;-5.64,1.51,;-4.74,.27,;-3.21,.43,;-2.58,1.83,;-1.12,2.31,;-7.13,1.11,;-6.73,-.37,;-8.22,.02,;-8.22,2.2,)| | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.260 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230151
(US9334290, 33)Show SMILES Cc1c(cccc1-n1c(=O)cc2c(Cl)cccn2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(1.33,8.47,;1.33,6.93,;,6.16,;,4.62,;1.33,3.85,;2.67,4.62,;2.67,6.16,;4,6.93,;4,8.47,;2.67,9.24,;5.33,9.24,;6.67,8.47,;8,9.24,;8,10.78,;9.34,8.47,;9.34,6.93,;8,6.16,;6.67,6.93,;5.33,6.16,;5.33,4.62,;-1.33,6.93,;-1.33,8.47,;,9.24,;-2.67,9.24,;-4,8.47,;-5.33,9.24,;-6.67,8.47,;-5.33,10.78,;-4,6.93,;-5.15,5.9,;-4.52,4.49,;-5.15,3.09,;-4.24,1.84,;-2.71,2,;-2.08,3.41,;-2.99,4.65,;-2.67,6.16,;-4.87,.43,;-5.49,-.97,;-3.46,-.19,;-6.27,1.06,)| Show InChI InChI=1S/C31H24Cl2N4O4/c1-15-17(6-4-8-23(15)37-25(38)14-24-20(32)7-5-11-36(24)30(37)40)26-21(33)13-19(29(34)39)28-27(26)18-10-9-16(31(2,3)41)12-22(18)35-28/h4-14,35,41H,1-3H3,(H2,34,39) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| Purchase
MCE
PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.260 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230148
(US9334290, 16)Show SMILES Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1c(cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O)C#N |(8,6.16,;9.34,6.93,;10.67,6.16,;12,6.93,;12,8.47,;10.67,9.24,;9.34,8.47,;8,9.24,;8,10.78,;9.34,11.55,;6.67,11.55,;6.67,13.09,;5.33,10.78,;4,11.55,;4,13.09,;2.67,10.78,;2.67,9.24,;4,8.47,;5.33,9.24,;6.67,8.47,;6.67,6.93,;10.67,4.62,;9.34,3.85,;9.34,2.31,;10.67,1.54,;10.67,,;12,-.77,;9.34,-.77,;12,2.31,;13.47,1.83,;14.37,3.08,;15.9,3.24,;16.53,4.65,;15.63,5.89,;14.09,5.73,;13.47,4.33,;12,3.85,;18.06,4.81,;19.59,4.97,;17.9,6.34,;18.22,3.28,;8,4.62,;6.67,5.39,)| Show InChI InChI=1S/C33H26FN5O4/c1-16-19(7-6-10-25(16)39-31(41)21-8-5-9-23(34)29(21)38(4)32(39)42)26-17(15-35)13-22(30(36)40)28-27(26)20-12-11-18(33(2,3)43)14-24(20)37-28/h5-14,37,43H,1-4H3,(H2,36,40) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.270 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230152
(US9334290, 36)Show SMILES Cc1c(cccc1-n1c(=O)cc2c(F)cccn2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(1.33,8.47,;1.33,6.93,;,6.16,;,4.62,;1.33,3.85,;2.67,4.62,;2.67,6.16,;4,6.93,;4,8.47,;2.67,9.24,;5.33,9.24,;6.67,8.47,;8,9.24,;8,10.78,;9.34,8.47,;9.34,6.93,;8,6.16,;6.67,6.93,;5.33,6.16,;5.33,4.62,;-1.33,6.93,;-1.33,8.47,;,9.24,;-2.67,9.24,;-4,8.47,;-5.33,9.24,;-6.67,8.47,;-5.33,10.78,;-4,6.93,;-5.15,5.9,;-4.52,4.49,;-5.15,3.09,;-4.24,1.84,;-2.71,2,;-2.08,3.41,;-2.99,4.65,;-2.67,6.16,;-4.87,.43,;-5.49,-.97,;-3.46,-.19,;-6.27,1.06,)| Show InChI InChI=1S/C31H24ClFN4O4/c1-15-17(6-4-8-23(15)37-25(38)14-24-21(33)7-5-11-36(24)30(37)40)26-20(32)13-19(29(34)39)28-27(26)18-10-9-16(31(2,3)41)12-22(18)35-28/h4-14,35,41H,1-3H3,(H2,34,39) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.280 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230122
(US10106559, Example 51 | US10435415, Example 51 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2cc(F)ccc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,-.77,;.88,-1.54,;-.45,-.77,;-1.78,-1.54,;-1.78,-3.08,;-.45,-3.85,;.88,-3.08,;2.22,-3.85,;2.22,-5.39,;.88,-6.16,;3.55,-6.16,;4.89,-5.39,;6.22,-6.16,;7.55,-5.39,;8.89,-6.16,;7.55,-3.85,;6.22,-3.08,;4.89,-3.85,;3.55,-3.08,;3.55,-1.54,;-.45,.77,;.88,1.54,;2.22,.77,;.88,3.08,;-.45,3.85,;-.45,5.39,;.88,6.16,;-1.78,6.16,;-1.78,3.08,;-3.25,3.56,;-4.15,2.31,;-5.68,2.15,;-6.31,.74,;-5.41,-.5,;-3.87,-.34,;-3.25,1.06,;-1.78,1.54,;-7.8,.34,;-7.4,-1.14,;-8.89,-.75,;-8.89,1.43,)| Show InChI InChI=1S/C31H24F2N4O4/c1-14-17(5-4-6-24(14)37-29(39)19-10-8-16(32)12-23(19)36-30(37)40)25-21(33)13-20(28(34)38)27-26(25)18-9-7-15(31(2,3)41)11-22(18)35-27/h4-13,35,41H,1-3H3,(H2,34,38)(H,36,40) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.300 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230153
(US9334290, 39)Show SMILES Cc1c(cccc1-n1c(=O)cc2sccn2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(12.93,9,;12.93,10.54,;14.26,11.31,;14.26,12.85,;12.93,13.62,;11.59,12.85,;11.59,11.31,;10.26,10.54,;10.26,9,;11.59,8.23,;8.92,8.23,;7.59,9,;6.13,8.53,;5.22,9.77,;6.13,11.02,;7.59,10.54,;8.92,11.31,;8.92,12.85,;15.59,10.54,;15.59,9,;14.26,8.23,;16.93,8.23,;18.26,9,;19.59,8.23,;20.93,9,;19.59,6.69,;18.26,10.54,;19.41,11.57,;18.78,12.98,;19.41,14.39,;18.5,15.63,;16.97,15.47,;16.34,14.07,;17.25,12.82,;16.93,11.31,;19.13,17.04,;19.75,18.45,;17.72,17.67,;20.53,16.41,)| Show InChI InChI=1S/C29H23ClN4O4S/c1-14-16(5-4-6-21(14)34-22(35)13-23-33(28(34)37)9-10-39-23)24-19(30)12-18(27(31)36)26-25(24)17-8-7-15(29(2,3)38)11-20(17)32-26/h4-13,32,38H,1-3H3,(H2,31,36) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.310 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.320 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230119
(US9334290, 48)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23ClF2N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(33)11-21(34)26(19)37-30(38)41)24-20(32)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.330 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230149
(US9334290, 22)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cccc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(8,6.16,;9.34,6.93,;10.67,6.16,;12,6.93,;12,8.47,;10.67,9.24,;9.34,8.47,;8,9.24,;8,10.78,;9.34,11.55,;6.67,11.55,;5.33,10.78,;4,11.55,;4,13.09,;2.67,10.78,;2.67,9.24,;4,8.47,;5.33,9.24,;6.67,8.47,;6.67,6.93,;10.67,4.62,;9.34,3.85,;8,4.62,;9.34,2.31,;10.67,1.54,;10.67,,;12,-.77,;9.34,-.77,;12,2.31,;13.47,1.83,;14.37,3.08,;15.9,3.24,;16.53,4.65,;15.63,5.89,;14.09,5.73,;13.47,4.33,;12,3.85,;18.06,4.81,;19.59,4.97,;17.9,6.34,;18.22,3.28,)| Show InChI InChI=1S/C31H24F2N4O4/c1-14-16(6-5-9-23(14)37-29(39)18-7-4-8-20(32)26(18)36-30(37)40)24-21(33)13-19(28(34)38)27-25(24)17-11-10-15(31(2,3)41)12-22(17)35-27/h4-13,35,41H,1-3H3,(H2,34,38)(H,36,40) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.330 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230099
(US10106559, Example 24 | US10435415, Example 24 | ...)Show SMILES Cc1c(cccc1-n1c(=O)ccn(-c2ccc(F)cc2)c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(1.42,-.77,;.08,-1.54,;-1.25,-.77,;-2.58,-1.54,;-2.58,-3.08,;-1.25,-3.85,;.08,-3.08,;1.42,-3.85,;1.42,-5.39,;.08,-6.16,;2.75,-6.16,;4.09,-5.39,;4.09,-3.85,;5.42,-3.08,;6.75,-3.85,;8.09,-3.08,;8.09,-1.54,;9.42,-.77,;6.75,-.77,;5.42,-1.54,;2.75,-3.08,;2.75,-1.54,;-1.25,.77,;.08,1.54,;1.42,.77,;.08,3.08,;-1.25,3.85,;-1.25,5.39,;.08,6.16,;-2.58,6.16,;-2.58,3.08,;-4.05,3.56,;-4.95,2.31,;-6.48,2.15,;-7.11,.74,;-6.21,-.5,;-4.67,-.34,;-4.05,1.06,;-2.58,1.54,;-8.65,.74,;-9.42,-.59,;-7.88,-.59,;-9.42,2.08,)| Show InChI InChI=1S/C33H26ClFN4O4/c1-17-21(5-4-6-26(17)39-27(40)13-14-38(32(39)42)20-10-8-19(35)9-11-20)28-24(34)16-23(31(36)41)30-29(28)22-12-7-18(33(2,3)43)15-25(22)37-30/h4-16,37,43H,1-3H3,(H2,36,41) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.330 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230111
(US10106559, Example 39 | US10435415, Example 39 | ...)Show SMILES Cc1c(cccc1-n1c(=O)cc2sccn2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(3.18,-.77,;1.85,-1.54,;.52,-.77,;-.82,-1.54,;-.82,-3.08,;.52,-3.85,;1.85,-3.08,;3.18,-3.85,;3.18,-5.39,;1.85,-6.16,;4.52,-6.16,;5.85,-5.39,;7.31,-5.87,;8.22,-4.62,;7.31,-3.37,;5.85,-3.85,;4.52,-3.08,;4.52,-1.54,;.52,.77,;1.85,1.54,;3.18,.77,;1.85,3.08,;.52,3.85,;.52,5.39,;1.85,6.16,;-.82,6.16,;-.82,3.08,;-2.28,3.56,;-3.19,2.31,;-4.72,2.15,;-5.35,.74,;-4.44,-.5,;-2.91,-.34,;-2.28,1.06,;-.82,1.54,;-6.89,.74,;-8.22,-.03,;-6.49,-.75,;-7.66,2.08,)| Show InChI InChI=1S/C29H23ClN4O4S/c1-14-16(5-4-6-21(14)34-22(35)13-23-33(28(34)37)9-10-39-23)24-19(30)12-18(27(31)36)26-25(24)17-8-7-15(29(2,3)38)11-20(17)32-26/h4-13,32,38H,1-3H3,(H2,31,36) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.340 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230135
(US9334290, 66)Show SMILES Cc1cc(C(N)=O)c2[nH]c3cc(ccc3c2c1-c1cccc(c1Cl)-n1c(=O)[nH]c2c(F)cccc2c1=O)C(C)(C)O |(2.89,1.54,;1.55,2.31,;1.55,3.85,;.22,4.62,;.22,6.16,;1.55,6.93,;-1.12,6.93,;-1.12,3.85,;-2.58,4.33,;-3.49,3.08,;-5.02,2.92,;-5.64,1.51,;-4.74,.27,;-3.21,.43,;-2.58,1.83,;-1.12,2.31,;.22,1.54,;.22,,;-1.12,-.77,;-1.12,-2.31,;.22,-3.08,;1.55,-2.31,;1.55,-.77,;2.89,,;2.89,-3.08,;2.89,-4.62,;1.55,-5.39,;4.22,-5.39,;5.55,-4.62,;6.89,-5.39,;6.89,-6.93,;8.22,-4.62,;8.22,-3.08,;6.89,-2.31,;5.55,-3.08,;4.22,-2.31,;4.22,-.77,;-7.13,1.11,;-6.73,-.37,;-8.22,.02,;-8.22,2.2,)| Show InChI InChI=1S/C31H24ClFN4O4/c1-14-12-19(28(34)38)27-24(16-11-10-15(31(2,3)41)13-21(16)35-27)23(14)17-6-5-9-22(25(17)32)37-29(39)18-7-4-8-20(33)26(18)36-30(37)40/h4-13,35,41H,1-3H3,(H2,34,38)(H,36,40) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.340 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230133
(US10106559, Example 65 | US10435415, Example 65 | ...)Show SMILES Cc1c(cccc1-n1c(=O)cc2c(Cl)cccn2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3C[C@H](CCc3c12)C(C)(C)O |r,wD:32.42,(2.89,,;1.55,-.77,;.22,,;-1.12,-.77,;-1.12,-2.31,;.22,-3.08,;1.55,-2.31,;2.89,-3.08,;2.89,-4.62,;1.55,-5.39,;4.22,-5.39,;5.55,-4.62,;6.89,-5.39,;6.89,-6.93,;8.22,-4.62,;8.22,-3.08,;6.89,-2.31,;5.55,-3.08,;4.22,-2.31,;4.22,-.77,;.22,1.54,;1.55,2.31,;2.89,1.54,;1.55,3.85,;.22,4.62,;.22,6.16,;1.55,6.93,;-1.12,6.93,;-1.12,3.85,;-2.58,4.33,;-3.49,3.08,;-5.02,2.92,;-5.64,1.51,;-4.74,.27,;-3.21,.43,;-2.58,1.83,;-1.12,2.31,;-7.13,1.11,;-6.73,-.37,;-8.22,.02,;-8.22,2.2,)| | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.340 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230124
(US10106559, Example 54 | US10435415, Example 54 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(Cl)cccc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.89,,;1.55,-.77,;.22,,;-1.12,-.77,;-1.12,-2.31,;.22,-3.08,;1.55,-2.31,;2.89,-3.08,;2.89,-4.62,;1.55,-5.39,;4.22,-5.39,;5.55,-4.62,;6.89,-5.39,;6.89,-6.93,;8.22,-4.62,;8.22,-3.08,;6.89,-2.31,;5.55,-3.08,;4.22,-2.31,;4.22,-.77,;.22,1.54,;1.55,2.31,;2.89,1.54,;1.55,3.85,;.22,4.62,;.22,6.16,;1.55,6.93,;-1.12,6.93,;-1.12,3.85,;-2.58,4.33,;-3.49,3.08,;-5.02,2.92,;-5.64,1.51,;-4.74,.27,;-3.21,.43,;-2.58,1.83,;-1.12,2.31,;-7.13,1.11,;-6.73,-.37,;-8.22,.02,;-8.22,2.2,)| Show InChI InChI=1S/C31H24ClFN4O4/c1-14-16(6-5-9-23(14)37-29(39)18-7-4-8-20(32)26(18)36-30(37)40)24-21(33)13-19(28(34)38)27-25(24)17-11-10-15(31(2,3)41)12-22(17)35-27/h4-13,35,41H,1-3H3,(H2,34,38)(H,36,40) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.350 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230118
(US10106559, Example 47 | US10435415, Example 47 | ...)Show SMILES CC(C)(O)c1ccc2c(c1)[nH]c1c(cc(Cl)c(-c3cccc(c3Cl)-n3c(=O)[nH]c4c(F)cccc4c3=O)c21)C(N)=O |(-8.37,.74,;-7.03,1.51,;-6.64,.02,;-7.8,2.85,;-5.49,1.51,;-4.59,.27,;-3.06,.43,;-2.43,1.83,;-3.34,3.08,;-4.87,2.92,;-2.43,4.33,;-.97,3.85,;.37,4.62,;1.7,3.85,;1.7,2.31,;3.03,1.54,;.37,1.54,;.37,,;-.97,-.77,;-.97,-2.31,;.37,-3.08,;1.7,-2.31,;1.7,-.77,;3.03,,;3.03,-3.08,;3.03,-4.62,;1.7,-5.39,;4.37,-5.39,;5.7,-4.62,;7.03,-5.39,;7.03,-6.93,;8.37,-4.62,;8.37,-3.08,;7.03,-2.31,;5.7,-3.08,;4.37,-2.31,;4.37,-.77,;-.97,2.31,;.37,6.16,;1.7,6.93,;-.97,6.93,)| Show InChI InChI=1S/C30H21Cl2FN4O4/c1-30(2,41)13-9-10-14-20(11-13)35-26-17(27(34)38)12-18(31)22(23(14)26)15-5-4-8-21(24(15)32)37-28(39)16-6-3-7-19(33)25(16)36-29(37)40/h3-12,35,41H,1-2H3,(H2,34,38)(H,36,40) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.350 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230089
(US10106559, Example 12 | US10435415, Example 12 | ...)Show SMILES Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.75,,;1.42,-.77,;.08,,;-1.25,-.77,;-1.25,-2.31,;.08,-3.08,;1.42,-2.31,;2.75,-3.08,;2.75,-4.62,;1.42,-5.39,;4.09,-5.39,;4.09,-6.93,;5.42,-4.62,;6.75,-5.39,;6.75,-6.93,;8.09,-4.62,;8.09,-3.08,;6.75,-2.31,;5.42,-3.08,;4.09,-2.31,;4.09,-.77,;.08,1.54,;1.42,2.31,;2.75,1.54,;1.42,3.85,;.08,4.62,;.08,6.16,;1.42,6.93,;-1.25,6.93,;-1.25,3.85,;-2.71,4.33,;-3.62,3.08,;-5.15,2.92,;-5.78,1.51,;-4.87,.27,;-3.34,.43,;-2.71,1.83,;-1.25,2.31,;-7.32,1.51,;-8.09,.18,;-6.55,.18,;-8.09,2.85,)| Show InChI InChI=1S/C32H26ClFN4O4/c1-15-17(7-6-10-24(15)38-30(40)19-8-5-9-22(34)28(19)37(4)31(38)41)25-21(33)14-20(29(35)39)27-26(25)18-12-11-16(32(2,3)42)13-23(18)36-27/h5-14,36,42H,1-4H3,(H2,35,39) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.400 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230140
(US10106559, Example 71 | US10435415, Example 71 | ...)Show SMILES Cc1cc(C(N)=O)c2[nH]c3cc(ccc3c2c1-c1cccc(c1C)-n1c(=O)cc2c(Cl)cccn2c1=O)C(C)(C)O |(2.89,1.54,;1.55,2.31,;1.55,3.85,;.22,4.62,;.22,6.16,;1.55,6.93,;-1.12,6.93,;-1.12,3.85,;-2.58,4.33,;-3.49,3.08,;-5.02,2.92,;-5.64,1.51,;-4.74,.27,;-3.21,.43,;-2.58,1.83,;-1.12,2.31,;.22,1.54,;.22,,;-1.12,-.77,;-1.12,-2.31,;.22,-3.08,;1.55,-2.31,;1.55,-.77,;2.89,,;2.89,-3.08,;2.89,-4.62,;1.55,-5.39,;4.22,-5.39,;5.55,-4.62,;6.89,-5.39,;6.89,-6.93,;8.22,-4.62,;8.22,-3.08,;6.89,-2.31,;5.55,-3.08,;4.22,-2.31,;4.22,-.77,;-7.13,1.11,;-6.73,-.37,;-8.22,.02,;-8.22,2.2,)| Show InChI InChI=1S/C32H27ClN4O4/c1-16-13-21(30(34)39)29-28(20-11-10-18(32(3,4)41)14-23(20)35-29)27(16)19-7-5-9-24(17(19)2)37-26(38)15-25-22(33)8-6-12-36(25)31(37)40/h5-15,35,41H,1-4H3,(H2,34,39) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.410 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230130
(US10106559, Example 61 | US10435415, Example 61 | ...)Show SMILES Cn1c2c(F)cccc2c(=O)n(-c2cccc(c2Cl)-c2c(F)cc(C(N)=O)c3[nH]c4cc(ccc4c23)C(C)(C)O)c1=O |(4.22,-6.93,;4.22,-5.39,;5.55,-4.62,;6.89,-5.39,;6.89,-6.93,;8.22,-4.62,;8.22,-3.08,;6.89,-2.31,;5.55,-3.08,;4.22,-2.31,;4.22,-.77,;2.89,-3.08,;1.55,-2.31,;.22,-3.08,;-1.12,-2.31,;-1.12,-.77,;.22,,;1.55,-.77,;2.89,,;.22,1.54,;1.55,2.31,;2.89,1.54,;1.55,3.85,;.22,4.62,;.22,6.16,;1.55,6.93,;-1.12,6.93,;-1.12,3.85,;-2.58,4.33,;-3.49,3.08,;-5.02,2.92,;-5.64,1.51,;-4.74,.27,;-3.21,.43,;-2.58,1.83,;-1.12,2.31,;-7.13,1.11,;-6.73,-.37,;-8.22,.02,;-8.22,2.2,;2.89,-4.62,;1.55,-5.39,)| Show InChI InChI=1S/C31H23ClF2N4O4/c1-31(2,42)14-10-11-15-21(12-14)36-26-18(28(35)39)13-20(34)23(24(15)26)16-6-5-9-22(25(16)32)38-29(40)17-7-4-8-19(33)27(17)37(3)30(38)41/h4-13,36,42H,1-3H3,(H2,35,39) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.410 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230099
(US10106559, Example 24 | US10435415, Example 24 | ...)Show SMILES Cc1c(cccc1-n1c(=O)ccn(-c2ccc(F)cc2)c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(1.42,-.77,;.08,-1.54,;-1.25,-.77,;-2.58,-1.54,;-2.58,-3.08,;-1.25,-3.85,;.08,-3.08,;1.42,-3.85,;1.42,-5.39,;.08,-6.16,;2.75,-6.16,;4.09,-5.39,;4.09,-3.85,;5.42,-3.08,;6.75,-3.85,;8.09,-3.08,;8.09,-1.54,;9.42,-.77,;6.75,-.77,;5.42,-1.54,;2.75,-3.08,;2.75,-1.54,;-1.25,.77,;.08,1.54,;1.42,.77,;.08,3.08,;-1.25,3.85,;-1.25,5.39,;.08,6.16,;-2.58,6.16,;-2.58,3.08,;-4.05,3.56,;-4.95,2.31,;-6.48,2.15,;-7.11,.74,;-6.21,-.5,;-4.67,-.34,;-4.05,1.06,;-2.58,1.54,;-8.65,.74,;-9.42,-.59,;-7.88,-.59,;-9.42,2.08,)| Show InChI InChI=1S/C33H26ClFN4O4/c1-17-21(5-4-6-26(17)39-27(40)13-14-38(32(39)42)20-10-8-19(35)9-11-20)28-24(34)16-23(31(36)41)30-29(28)22-12-7-18(33(2,3)43)15-25(22)37-30/h4-16,37,43H,1-3H3,(H2,36,41) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.440 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230132
(US10106559, Example 63 | US10435415, Example 63 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(Cl)cccc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3C[C@H](CCc3c12)C(C)(C)O |r,wD:32.42,(2.89,,;1.55,-.77,;.22,,;-1.12,-.77,;-1.12,-2.31,;.22,-3.08,;1.55,-2.31,;2.89,-3.08,;2.89,-4.62,;1.55,-5.39,;4.22,-5.39,;5.55,-4.62,;6.89,-5.39,;6.89,-6.93,;8.22,-4.62,;8.22,-3.08,;6.89,-2.31,;5.55,-3.08,;4.22,-2.31,;4.22,-.77,;.22,1.54,;1.55,2.31,;2.89,1.54,;1.55,3.85,;.22,4.62,;.22,6.16,;1.55,6.93,;-1.12,6.93,;-1.12,3.85,;-2.58,4.33,;-3.49,3.08,;-5.02,2.92,;-5.64,1.51,;-4.74,.27,;-3.21,.43,;-2.58,1.83,;-1.12,2.31,;-7.13,1.11,;-6.73,-.37,;-8.22,.02,;-8.22,2.2,)| | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.450 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230096
(US9334290, 19)Show SMILES Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.75,,;1.42,-.77,;.08,,;-1.25,-.77,;-1.25,-2.31,;.08,-3.08,;1.42,-2.31,;2.75,-3.08,;2.75,-4.62,;1.42,-5.39,;4.09,-5.39,;4.09,-6.93,;5.42,-4.62,;6.75,-5.39,;6.75,-6.93,;8.09,-4.62,;8.09,-3.08,;6.75,-2.31,;5.42,-3.08,;4.09,-2.31,;4.09,-.77,;.08,1.54,;1.42,2.31,;2.75,1.54,;1.42,3.85,;.08,4.62,;.08,6.16,;1.42,6.93,;-1.25,6.93,;-1.25,3.85,;-2.71,4.33,;-3.62,3.08,;-5.15,2.92,;-5.78,1.51,;-4.87,.27,;-3.34,.43,;-2.71,1.83,;-1.25,2.31,;-7.32,1.51,;-8.09,.18,;-6.55,.18,;-8.09,2.85,)| Show InChI InChI=1S/C32H26F2N4O4/c1-15-17(7-6-10-24(15)38-30(40)19-8-5-9-21(33)28(19)37(4)31(38)41)25-22(34)14-20(29(35)39)27-26(25)18-12-11-16(32(2,3)42)13-23(18)36-27/h5-14,36,42H,1-4H3,(H2,35,39) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.450 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230115
(US10106559, Example 45 | US10435415, Example 60 | ...)Show SMILES Cn1c2c(F)cccc2c(=O)n(-c2cccc(c2Cl)-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(ccc4c23)C(C)(C)O)c1=O |(4.37,-6.93,;4.37,-5.39,;5.7,-4.62,;7.03,-5.39,;7.03,-6.93,;8.37,-4.62,;8.37,-3.08,;7.03,-2.31,;5.7,-3.08,;4.37,-2.31,;4.37,-.77,;3.03,-3.08,;1.7,-2.31,;.37,-3.08,;-.97,-2.31,;-.97,-.77,;.37,,;1.7,-.77,;3.03,,;.37,1.54,;1.7,2.31,;3.03,1.54,;1.7,3.85,;.37,4.62,;.37,6.16,;1.7,6.93,;-.97,6.93,;-.97,3.85,;-2.43,4.33,;-3.34,3.08,;-4.87,2.92,;-5.49,1.51,;-4.59,.27,;-3.06,.43,;-2.43,1.83,;-.97,2.31,;-7.03,1.51,;-8.37,.74,;-6.64,.02,;-7.8,2.85,;3.03,-4.62,;1.7,-5.39,)| Show InChI InChI=1S/C31H23Cl2FN4O4/c1-31(2,42)14-10-11-15-21(12-14)36-26-18(28(35)39)13-19(32)23(24(15)26)16-6-5-9-22(25(16)33)38-29(40)17-7-4-8-20(34)27(17)37(3)30(38)41/h4-13,36,42H,1-3H3,(H2,35,39) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.450 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230097
(US10106559, Example 22 | US10435415, Example 22 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cccc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(3.03,,;1.7,-.77,;.37,,;-.97,-.77,;-.97,-2.31,;.37,-3.08,;1.7,-2.31,;3.03,-3.08,;3.03,-4.62,;1.7,-5.39,;4.37,-5.39,;5.7,-4.62,;7.03,-5.39,;7.03,-6.93,;8.37,-4.62,;8.37,-3.08,;7.03,-2.31,;5.7,-3.08,;4.37,-2.31,;4.37,-.77,;.37,1.54,;1.7,2.31,;3.03,1.54,;1.7,3.85,;.37,4.62,;.37,6.16,;1.7,6.93,;-.97,6.93,;-.97,3.85,;-2.43,4.33,;-3.34,3.08,;-4.87,2.92,;-5.49,1.51,;-4.59,.27,;-3.06,.43,;-2.43,1.83,;-.97,2.31,;-7.03,1.51,;-7.03,-.03,;-8.37,.74,;-7.8,2.85,)| Show InChI InChI=1S/C31H24F2N4O4/c1-14-16(6-5-9-23(14)37-29(39)18-7-4-8-20(32)26(18)36-30(37)40)24-21(33)13-19(28(34)38)27-25(24)17-11-10-15(31(2,3)41)12-22(17)35-27/h4-13,35,41H,1-3H3,(H2,34,38)(H,36,40) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.460 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230133
(US10106559, Example 65 | US10435415, Example 65 | ...)Show SMILES Cc1c(cccc1-n1c(=O)cc2c(Cl)cccn2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3C[C@H](CCc3c12)C(C)(C)O |r,wD:32.42,(2.89,,;1.55,-.77,;.22,,;-1.12,-.77,;-1.12,-2.31,;.22,-3.08,;1.55,-2.31,;2.89,-3.08,;2.89,-4.62,;1.55,-5.39,;4.22,-5.39,;5.55,-4.62,;6.89,-5.39,;6.89,-6.93,;8.22,-4.62,;8.22,-3.08,;6.89,-2.31,;5.55,-3.08,;4.22,-2.31,;4.22,-.77,;.22,1.54,;1.55,2.31,;2.89,1.54,;1.55,3.85,;.22,4.62,;.22,6.16,;1.55,6.93,;-1.12,6.93,;-1.12,3.85,;-2.58,4.33,;-3.49,3.08,;-5.02,2.92,;-5.64,1.51,;-4.74,.27,;-3.21,.43,;-2.58,1.83,;-1.12,2.31,;-7.13,1.11,;-6.73,-.37,;-8.22,.02,;-8.22,2.2,)| | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.460 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230112
(US10106559, Example 41 | US10435415, Example 41 | ...)Show SMILES Cc1c(cccc1-n1c(=O)cc2c(F)cccn2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(3.03,,;1.7,-.77,;.37,,;-.97,-.77,;-.97,-2.31,;.37,-3.08,;1.7,-2.31,;3.03,-3.08,;3.03,-4.62,;1.7,-5.39,;4.37,-5.39,;5.7,-4.62,;7.03,-5.39,;7.03,-6.93,;8.37,-4.62,;8.37,-3.08,;7.03,-2.31,;5.7,-3.08,;4.37,-2.31,;4.37,-.77,;.37,1.54,;1.7,2.31,;3.03,1.54,;1.7,3.85,;.37,4.62,;.37,6.16,;1.7,6.93,;-.97,6.93,;-.97,3.85,;-2.43,4.33,;-3.34,3.08,;-4.87,2.92,;-5.49,1.51,;-4.59,.27,;-3.06,.43,;-2.43,1.83,;-.97,2.31,;-7.03,1.51,;-8.37,.74,;-6.64,.02,;-7.8,2.85,)| Show InChI InChI=1S/C31H24F2N4O4/c1-15-17(6-4-8-23(15)37-25(38)14-24-20(32)7-5-11-36(24)30(37)40)26-21(33)13-19(29(34)39)28-27(26)18-10-9-16(31(2,3)41)12-22(18)35-28/h4-14,35,41H,1-3H3,(H2,34,39) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.460 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230113
(US10106559, Example 43 | US10435415, Example 43 | ...)Show SMILES Cn1c2ccccc2c(=O)n(-c2cccc(c2Cl)-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(ccc4c23)C(C)(C)O)c1=O |(4.37,-6.93,;4.37,-5.39,;5.7,-4.62,;7.03,-5.39,;8.37,-4.62,;8.37,-3.08,;7.03,-2.31,;5.7,-3.08,;4.37,-2.31,;4.37,-.77,;3.03,-3.08,;1.7,-2.31,;.37,-3.08,;-.97,-2.31,;-.97,-.77,;.37,,;1.7,-.77,;3.03,,;.37,1.54,;1.7,2.31,;3.03,1.54,;1.7,3.85,;.37,4.62,;.37,6.16,;1.7,6.93,;-.97,6.93,;-.97,3.85,;-2.43,4.33,;-3.34,3.08,;-4.87,2.92,;-5.49,1.51,;-4.59,.27,;-3.06,.43,;-2.43,1.83,;-.97,2.31,;-7.03,1.51,;-8.37,.74,;-6.64,.02,;-7.8,2.85,;3.03,-4.62,;1.7,-5.39,)| Show InChI InChI=1S/C31H24Cl2N4O4/c1-31(2,41)15-11-12-16-21(13-15)35-27-19(28(34)38)14-20(32)24(25(16)27)18-8-6-10-23(26(18)33)37-29(39)17-7-4-5-9-22(17)36(3)30(37)40/h4-14,35,41H,1-3H3,(H2,34,38) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.470 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230098
(US9334290, 21)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cccc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.75,9.88,;1.42,9.11,;.08,9.88,;-1.25,9.11,;-1.25,7.57,;.08,6.8,;1.42,7.57,;2.75,6.8,;2.75,5.26,;1.42,4.49,;4.09,4.49,;5.42,5.26,;6.75,4.49,;6.75,2.95,;8.09,5.26,;8.09,6.8,;6.75,7.57,;5.42,6.8,;4.09,7.57,;4.09,9.11,;.08,11.42,;1.42,12.19,;2.75,11.42,;1.42,13.73,;.08,14.5,;.08,16.04,;1.42,16.81,;-1.25,16.81,;-1.25,13.73,;-2.71,14.2,;-3.62,12.96,;-5.15,12.8,;-5.78,11.39,;-4.87,10.14,;-3.34,10.31,;-2.71,11.71,;-1.25,12.19,;-7.32,11.39,;-8.09,10.06,;-6.55,10.06,;-8.09,12.72,)| Show InChI InChI=1S/C31H24F2N4O4/c1-14-16(6-5-9-23(14)37-29(39)18-7-4-8-20(32)26(18)36-30(37)40)24-21(33)13-19(28(34)38)27-25(24)17-11-10-15(31(2,3)41)12-22(17)35-27/h4-13,35,41H,1-3H3,(H2,34,38)(H,36,40) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.480 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230123
(US9334290, 52)Show SMILES Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.89,.77,;1.55,,;.22,.77,;-1.12,,;-1.12,-1.54,;.22,-2.31,;1.55,-1.54,;2.89,-2.31,;2.89,-3.85,;1.55,-4.62,;4.22,-4.62,;4.22,-6.16,;5.55,-3.85,;6.89,-4.62,;6.89,-6.16,;8.22,-3.85,;8.22,-2.31,;6.89,-1.54,;5.55,-2.31,;4.22,-1.54,;4.22,,;.22,2.31,;1.55,3.08,;2.89,2.31,;1.55,4.62,;.22,5.39,;.22,6.93,;1.55,7.7,;-1.12,7.7,;-1.12,4.62,;-2.58,5.1,;-3.49,3.85,;-5.02,3.69,;-5.64,2.28,;-4.74,1.04,;-3.21,1.2,;-2.58,2.6,;-1.12,3.08,;-7.13,1.88,;-6.73,.4,;-8.22,.79,;-8.22,2.97,)| Show InChI InChI=1S/C32H26F2N4O4/c1-15-17(7-6-10-24(15)38-30(40)19-8-5-9-21(33)28(19)37(4)31(38)41)25-22(34)14-20(29(35)39)27-26(25)18-12-11-16(32(2,3)42)13-23(18)36-27/h5-14,36,42H,1-4H3,(H2,35,39) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.480 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230141
(US10106559, Example 72 | US10435415, Example 72 | ...)Show SMILES Cc1c(cccc1-n1c(=O)cc2c(Cl)cccn2c1=O)-c1c(cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O)C#N |(2.89,,;1.55,-.77,;.22,,;-1.12,-.77,;-1.12,-2.31,;.22,-3.08,;1.55,-2.31,;2.89,-3.08,;2.89,-4.62,;1.55,-5.39,;4.22,-5.39,;5.55,-4.62,;6.89,-5.39,;6.89,-6.93,;8.22,-4.62,;8.22,-3.08,;6.89,-2.31,;5.55,-3.08,;4.22,-2.31,;4.22,-.77,;.22,1.54,;1.55,2.31,;1.55,3.85,;.22,4.62,;.22,6.16,;1.55,6.93,;-1.12,6.93,;-1.12,3.85,;-2.58,4.33,;-3.49,3.08,;-5.02,2.92,;-5.64,1.51,;-4.74,.27,;-3.21,.43,;-2.58,1.83,;-1.12,2.31,;-7.13,1.11,;-6.73,-.37,;-8.22,.02,;-8.22,2.2,;2.89,1.54,;4.22,.77,)| Show InChI InChI=1S/C32H24ClN5O4/c1-16-19(6-4-8-24(16)38-26(39)14-25-22(33)7-5-11-37(25)31(38)41)27-17(15-34)12-21(30(35)40)29-28(27)20-10-9-18(32(2,3)42)13-23(20)36-29/h4-14,36,42H,1-3H3,(H2,35,40) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.490 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230136
(US10106559, Example 67 | US10435415, Example 67 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cccc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3C[C@@H](CCc3c12)C(C)(C)O |r,wU:32.42,(2.89,,;1.55,-.77,;.22,,;-1.12,-.77,;-1.12,-2.31,;.22,-3.08,;1.55,-2.31,;2.89,-3.08,;2.89,-4.62,;1.55,-5.39,;4.22,-5.39,;5.55,-4.62,;6.89,-5.39,;6.89,-6.93,;8.22,-4.62,;8.22,-3.08,;6.89,-2.31,;5.55,-3.08,;4.22,-2.31,;4.22,-.77,;.22,1.54,;1.55,2.31,;2.89,1.54,;1.55,3.85,;.22,4.62,;.22,6.16,;1.55,6.93,;-1.12,6.93,;-1.12,3.85,;-2.58,4.33,;-3.49,3.08,;-5.02,2.92,;-5.64,1.51,;-4.74,.27,;-3.21,.43,;-2.58,1.83,;-1.12,2.31,;-7.13,1.11,;-6.73,-.37,;-8.22,.02,;-8.22,2.2,)| | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.490 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230104
(US10106559, Example 62 | US10435415, Example 62 | ...)Show SMILES Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3C[C@H](CCc3c12)C(C)(C)O |r,wD:33.43,(3.03,,;1.7,-.77,;.37,,;-.97,-.77,;-.97,-2.31,;.37,-3.08,;1.7,-2.31,;3.03,-3.08,;3.03,-4.62,;1.7,-5.39,;4.37,-5.39,;4.37,-6.93,;5.7,-4.62,;7.03,-5.39,;7.03,-6.93,;8.37,-4.62,;8.37,-3.08,;7.03,-2.31,;5.7,-3.08,;4.37,-2.31,;4.37,-.77,;.37,1.54,;1.7,2.31,;3.03,1.54,;1.7,3.85,;.37,4.62,;.37,6.16,;1.7,6.93,;-.97,6.93,;-.97,3.85,;-2.43,4.33,;-3.34,3.08,;-4.87,2.92,;-5.49,1.51,;-4.59,.27,;-3.06,.43,;-2.43,1.83,;-.97,2.31,;-7.03,1.51,;-7.03,-.03,;-8.37,.74,;-7.8,2.85,)| | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| Purchase
MCE
PC cid
PC sid
PDB
UniChem
| PDB
US Patent
| n/a | n/a | 0.540 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | 
3D Structure (crystal) |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230107
(US10106559, Example 33 | US10435415, Example 33 | ...)Show SMILES Cc1c(cccc1-n1c(=O)cc2c(Cl)cccn2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(3.03,8.9,;1.7,8.13,;.37,8.9,;-.97,8.13,;-.97,6.59,;.37,5.82,;1.7,6.59,;3.03,5.82,;3.03,4.28,;1.7,3.51,;4.37,3.51,;5.7,4.28,;7.03,3.51,;7.03,1.97,;8.37,4.28,;8.37,5.82,;7.03,6.59,;5.7,5.82,;4.37,6.59,;4.37,8.13,;.37,10.44,;1.7,11.21,;3.03,10.44,;1.7,12.75,;.37,13.52,;.37,15.06,;1.7,15.83,;-.97,15.83,;-.97,12.75,;-2.43,13.22,;-3.34,11.98,;-4.87,11.82,;-5.49,10.41,;-4.59,9.16,;-3.06,9.32,;-2.43,10.73,;-.97,11.21,;-7.03,10.41,;-6.64,8.92,;-8.37,9.64,;-7.8,11.74,)| Show InChI InChI=1S/C31H24Cl2N4O4/c1-15-17(6-4-8-23(15)37-25(38)14-24-20(32)7-5-11-36(24)30(37)40)26-21(33)13-19(29(34)39)28-27(26)18-10-9-16(31(2,3)41)12-22(18)35-28/h4-14,35,41H,1-3H3,(H2,34,39) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| Purchase
MCE
PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.550 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230137
(US10106559, Example 69 | US10435415, Example 69 | ...)Show SMILES Cc1c(cccc1-n1c(=O)cc2c(F)cccn2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3C[C@H](CCc3c12)C(C)(C)O |r,wD:32.42,(2.89,,;1.55,-.77,;.22,,;-1.12,-.77,;-1.12,-2.31,;.22,-3.08,;1.55,-2.31,;2.89,-3.08,;2.89,-4.62,;1.55,-5.39,;4.22,-5.39,;5.55,-4.62,;6.89,-5.39,;6.89,-6.93,;8.22,-4.62,;8.22,-3.08,;6.89,-2.31,;5.55,-3.08,;4.22,-2.31,;4.22,-.77,;.22,1.54,;1.55,2.31,;2.89,1.54,;1.55,3.85,;.22,4.62,;.22,6.16,;1.55,6.93,;-1.12,6.93,;-1.12,3.85,;-2.58,4.33,;-3.49,3.08,;-5.02,2.92,;-5.64,1.51,;-4.74,.27,;-3.21,.43,;-2.58,1.83,;-1.12,2.31,;-7.13,1.11,;-6.73,-.37,;-8.22,.02,;-8.22,2.2,)| | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.560 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230139
(US10106559, Example 70 | US10435415, Example 70 | ...)Show SMILES Cc1c(cccc1-n1c(=O)cc2c(F)cccn2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(CCO)ccc3c12 |(3.63,,;2.3,-.77,;.96,,;-.37,-.77,;-.37,-2.31,;.96,-3.08,;2.3,-2.31,;3.63,-3.08,;3.63,-4.62,;2.3,-5.39,;4.96,-5.39,;6.3,-4.62,;7.63,-5.39,;7.63,-6.93,;8.96,-4.62,;8.96,-3.08,;7.63,-2.31,;6.3,-3.08,;4.96,-2.31,;4.96,-.77,;.96,1.54,;2.3,2.31,;3.63,1.54,;2.3,3.85,;.96,4.62,;.96,6.16,;2.3,6.93,;-.37,6.93,;-.37,3.85,;-1.84,4.33,;-2.74,3.08,;-4.27,2.92,;-4.9,1.51,;-6.39,1.11,;-7.48,2.2,;-8.96,1.8,;-3.99,.27,;-2.46,.43,;-1.84,1.83,;-.37,2.31,)| Show InChI InChI=1S/C30H22F2N4O4/c1-15-17(4-2-6-23(15)36-25(38)14-24-20(31)5-3-10-35(24)30(36)40)26-21(32)13-19(29(33)39)28-27(26)18-8-7-16(9-11-37)12-22(18)34-28/h2-8,10,12-14,34,37H,9,11H2,1H3,(H2,33,39) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.590 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230094
(US10106559, Example 74 | US10435415, Example 52 | ...)Show SMILES Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(3.03,,;1.7,-.77,;.37,,;-.97,-.77,;-.97,-2.31,;.37,-3.08,;1.7,-2.31,;3.03,-3.08,;3.03,-4.62,;1.7,-5.39,;4.37,-5.39,;4.37,-6.93,;5.7,-4.62,;7.03,-5.39,;7.03,-6.93,;8.37,-4.62,;8.37,-3.08,;7.03,-2.31,;5.7,-3.08,;4.37,-2.31,;4.37,-.77,;.37,1.54,;1.7,2.31,;3.03,1.54,;1.7,3.85,;.37,4.62,;.37,6.16,;1.7,6.93,;-.97,6.93,;-.97,3.85,;-2.43,4.33,;-3.34,3.08,;-4.87,2.92,;-5.49,1.51,;-4.59,.27,;-3.06,.43,;-2.43,1.83,;-.97,2.31,;-7.03,1.51,;-7.03,-.03,;-8.37,.74,;-7.8,2.85,)| Show InChI InChI=1S/C32H26F2N4O4/c1-15-17(7-6-10-24(15)38-30(40)19-8-5-9-21(33)28(19)37(4)31(38)41)25-22(34)14-20(29(35)39)27-26(25)18-12-11-16(32(2,3)42)13-23(18)36-27/h5-14,36,42H,1-4H3,(H2,35,39) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.590 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230126
(US10106559, Example 56 | US10435415, Example 59 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cccc2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3C[C@H](CCc3c12)C(C)(C)O |r,wD:32.42,(2.89,,;1.55,-.77,;.22,,;-1.12,-.77,;-1.12,-2.31,;.22,-3.08,;1.55,-2.31,;2.89,-3.08,;2.89,-4.62,;1.55,-5.39,;4.22,-5.39,;5.55,-4.62,;6.89,-5.39,;6.89,-6.93,;8.22,-4.62,;8.22,-3.08,;6.89,-2.31,;5.55,-3.08,;4.22,-2.31,;4.22,-.77,;.22,1.54,;1.55,2.31,;2.89,1.54,;1.55,3.85,;.22,4.62,;.22,6.16,;1.55,6.93,;-1.12,6.93,;-1.12,3.85,;-2.58,4.33,;-3.49,3.08,;-5.02,2.92,;-5.64,1.51,;-4.74,.27,;-3.21,.43,;-2.58,1.83,;-1.12,2.31,;-7.13,1.11,;-6.73,-.37,;-8.22,.02,;-8.22,2.2,)| | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.620 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230087
(US10106559, Example 9 | US10435415, Example 9 | US...)Show SMILES Cc1c(cccc1-n1c(=O)n(C)c2cc(F)ccc2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.09,,;.75,-.77,;-.58,,;-1.92,-.77,;-1.92,-2.31,;-.58,-3.08,;.75,-2.31,;2.09,-3.08,;2.09,-4.62,;.75,-5.39,;3.42,-5.39,;3.42,-6.93,;4.75,-4.62,;6.09,-5.39,;7.42,-4.62,;8.75,-5.39,;7.42,-3.08,;6.09,-2.31,;4.75,-3.08,;3.42,-2.31,;3.42,-.77,;-.58,1.54,;.75,2.31,;2.09,1.54,;.75,3.85,;-.58,4.62,;-.58,6.16,;.75,6.93,;-1.92,6.93,;-1.92,3.85,;-3.38,4.33,;-4.29,3.08,;-5.82,2.92,;-6.44,1.51,;-5.54,.27,;-4.01,.43,;-3.38,1.83,;-1.92,2.31,;-7.98,1.51,;-8.75,.18,;-7.21,.18,;-8.75,2.85,)| Show InChI InChI=1S/C32H26ClFN4O4/c1-15-18(6-5-7-24(15)38-30(40)20-11-9-17(34)13-25(20)37(4)31(38)41)26-22(33)14-21(29(35)39)28-27(26)19-10-8-16(32(2,3)42)12-23(19)36-28/h5-14,36,42H,1-4H3,(H2,35,39) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.620 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230094
(US10106559, Example 74 | US10435415, Example 52 | ...)Show SMILES Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(3.03,,;1.7,-.77,;.37,,;-.97,-.77,;-.97,-2.31,;.37,-3.08,;1.7,-2.31,;3.03,-3.08,;3.03,-4.62,;1.7,-5.39,;4.37,-5.39,;4.37,-6.93,;5.7,-4.62,;7.03,-5.39,;7.03,-6.93,;8.37,-4.62,;8.37,-3.08,;7.03,-2.31,;5.7,-3.08,;4.37,-2.31,;4.37,-.77,;.37,1.54,;1.7,2.31,;3.03,1.54,;1.7,3.85,;.37,4.62,;.37,6.16,;1.7,6.93,;-.97,6.93,;-.97,3.85,;-2.43,4.33,;-3.34,3.08,;-4.87,2.92,;-5.49,1.51,;-4.59,.27,;-3.06,.43,;-2.43,1.83,;-.97,2.31,;-7.03,1.51,;-7.03,-.03,;-8.37,.74,;-7.8,2.85,)| Show InChI InChI=1S/C32H26F2N4O4/c1-15-17(7-6-10-24(15)38-30(40)19-8-5-9-21(33)28(19)37(4)31(38)41)25-22(34)14-20(29(35)39)27-26(25)18-12-11-16(32(2,3)42)13-23(18)36-27/h5-14,36,42H,1-4H3,(H2,35,39) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.650 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230086
(US10106559, Example 8 | US10435415, Example 8 | US...)Show SMILES Cc1c(cccc1-n1c(=O)n(C)c2ccc(F)cc2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.09,,;.75,-.77,;-.58,,;-1.92,-.77,;-1.92,-2.31,;-.58,-3.08,;.75,-2.31,;2.09,-3.08,;2.09,-4.62,;.75,-5.39,;3.42,-5.39,;3.42,-6.93,;4.75,-4.62,;6.09,-5.39,;7.42,-4.62,;7.42,-3.08,;8.75,-2.31,;6.09,-2.31,;4.75,-3.08,;3.42,-2.31,;3.42,-.77,;-.58,1.54,;.75,2.31,;2.09,1.54,;.75,3.85,;-.58,4.62,;-.58,6.16,;.75,6.93,;-1.92,6.93,;-1.92,3.85,;-3.38,4.33,;-4.29,3.08,;-5.82,2.92,;-6.44,1.51,;-5.54,.27,;-4.01,.43,;-3.38,1.83,;-1.92,2.31,;-7.98,1.51,;-8.75,.18,;-7.21,.18,;-8.75,2.85,)| Show InChI InChI=1S/C32H26ClFN4O4/c1-15-18(6-5-7-24(15)38-30(40)20-13-17(34)9-11-25(20)37(4)31(38)41)26-22(33)14-21(29(35)39)28-27(26)19-10-8-16(32(2,3)42)12-23(19)36-28/h5-14,36,42H,1-4H3,(H2,35,39) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.650 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230105
(US10106559, Example 29 | US10435415, Example 29 | ...)Show SMILES Cc1cc(C(N)=O)c2[nH]c3cc(ccc3c2c1-c1cccc(c1C)-n1c(=O)n(C)c2c(F)cccc2c1=O)C(C)(C)O |(3.03,1.54,;1.7,2.31,;1.7,3.85,;.37,4.62,;.37,6.16,;1.7,6.93,;-.97,6.93,;-.97,3.85,;-2.43,4.33,;-3.34,3.08,;-4.87,2.92,;-5.49,1.51,;-4.59,.27,;-3.06,.43,;-2.43,1.83,;-.97,2.31,;.37,1.54,;.37,,;-.97,-.77,;-.97,-2.31,;.37,-3.08,;1.7,-2.31,;1.7,-.77,;3.03,,;3.03,-3.08,;3.03,-4.62,;1.7,-5.39,;4.37,-5.39,;4.37,-6.93,;5.7,-4.62,;7.03,-5.39,;7.03,-6.93,;8.37,-4.62,;8.37,-3.08,;7.03,-2.31,;5.7,-3.08,;4.37,-2.31,;4.37,-.77,;-7.03,1.51,;-7.03,-.03,;-8.37,.74,;-7.8,2.85,)| Show InChI InChI=1S/C33H29FN4O4/c1-16-14-22(30(35)39)28-27(20-13-12-18(33(3,4)42)15-24(20)36-28)26(16)19-8-7-11-25(17(19)2)38-31(40)21-9-6-10-23(34)29(21)37(5)32(38)41/h6-15,36,42H,1-5H3,(H2,35,39) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.660 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.770 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230143
(US9334290, 74)Show SMILES Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.89,,;1.55,-.77,;.22,,;-1.12,-.77,;-1.12,-2.31,;.22,-3.08,;1.55,-2.31,;2.89,-3.08,;2.89,-4.62,;1.55,-5.39,;4.22,-5.39,;4.22,-6.93,;5.55,-4.62,;6.89,-5.39,;6.89,-6.93,;8.22,-4.62,;8.22,-3.08,;6.89,-2.31,;5.55,-3.08,;4.22,-2.31,;4.22,-.77,;.22,1.54,;1.55,2.31,;2.89,1.54,;1.55,3.85,;.22,4.62,;.22,6.16,;1.55,6.93,;-1.12,6.93,;-1.12,3.85,;-2.58,4.33,;-3.49,3.08,;-5.02,2.92,;-5.64,1.51,;-4.74,.27,;-3.21,.43,;-2.58,1.83,;-1.12,2.31,;-7.13,1.11,;-6.73,-.37,;-8.22,.02,;-8.22,2.2,)| Show InChI InChI=1S/C32H26F2N4O4/c1-15-17(7-6-10-24(15)38-30(40)19-8-5-9-21(33)28(19)37(4)31(38)41)25-22(34)14-20(29(35)39)27-26(25)18-12-11-16(32(2,3)42)13-23(18)36-27/h5-14,36,42H,1-4H3,(H2,35,39) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.790 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230085
(US10106559, Example 7 | US10435415, Example 7 | US...)Show SMILES COc1cccc2c1n(C)c(=O)n(-c1cccc(c1C)-c1c(Cl)cc(C(N)=O)c3[nH]c4cc(ccc4c13)C(C)(C)O)c2=O |(8.09,-7.31,;6.75,-6.54,;6.75,-5,;8.09,-4.23,;8.09,-2.69,;6.75,-1.92,;5.42,-2.69,;5.42,-4.23,;4.09,-5,;4.09,-6.54,;2.75,-4.23,;1.42,-5,;2.75,-2.69,;1.42,-1.93,;.08,-2.69,;-1.25,-1.93,;-1.25,-.38,;.08,.38,;1.42,-.38,;2.75,.38,;.08,1.93,;1.42,2.69,;2.75,1.93,;1.42,4.23,;.08,5,;.08,6.54,;1.42,7.31,;-1.25,7.31,;-1.25,4.23,;-2.71,4.71,;-3.62,3.47,;-5.15,3.3,;-5.78,1.9,;-4.87,.65,;-3.34,.81,;-2.71,2.22,;-1.25,2.69,;-7.32,1.9,;-8.09,.56,;-6.55,.56,;-8.09,3.23,;4.09,-1.93,;4.09,-.38,)| Show InChI InChI=1S/C33H29ClN4O5/c1-16-18(8-6-10-24(16)38-31(40)20-9-7-11-25(43-5)29(20)37(4)32(38)41)26-22(34)15-21(30(35)39)28-27(26)19-13-12-17(33(2,3)42)14-23(19)36-28/h6-15,36,42H,1-5H3,(H2,35,39) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.810 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this
Ligand-Target Pair | |
Search and Browse
